Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 89 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sacituzumab Clear all

Conditions: Non Small Cell Lung Cancer
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Paclitaxel, Rescue medication; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 52
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Beverly Hills, California + 42 more

Conditions: Breast Cancer, Triple Negative Breast Cancer
Interventions: Stereotactic Radiation, Zimberelimab, Sacituzumab govitecan; Radiation · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Bladder Cancer
Interventions: Sacituzumab tirumotecan, Vinflunine, Docetaxel, Paclitaxel, Rescue medications for sacituzumab tirumotecan, Rescue medications for chemotherapy; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 19
States / cities: Newport Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 15 more

Conditions: Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma
Interventions: Sacituzumab govitecan, Adaptive Radiotherapy; Drug · Radiation
Lead sponsor: Shilpa Gupta, MD; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Metastatic Breast Cancer
Interventions: Sacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, Vinorelbine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 543 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 55
States / cities: Avondale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 40 more

Conditions: Non-small Cell Lung Cancer
Interventions: Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Carboplatin, Cisplatin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 22
States / cities: Anchorage, Alaska • Beverly Hills, California • Los Angeles, California + 17 more

Conditions: Triple Negative Breast Cancer, PD-L1 Positive
Interventions: Sacituzumab Govitecan-hziy, Pembrolizumab, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 247
States / cities: Anchorage, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 175 more

Conditions: Ovarian Clear Cell Carcinoma, Metastatic Ovarian Cancer, Recurrent Ovarian Clear Cell Adenocarcinoma
Interventions: Sacituzumab tirumotecan, Pembrolizumab; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-Muscle Invasive Bladder Cancer
Interventions: Sacituzumab tirumotecan, Rescue medication, Supportive care measures; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Bakersfield, California • Tampa, Florida • Chicago, Illinois + 1 more

Conditions: Phase II, Sacituzumab, Tirumotecan, SMARCB1-deficient Renal Medullary Carcinoma
Interventions: Sacituzumab tirumotecan; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Triple Negative Breast Cancer, PD-L1 Negative
Interventions: Sacituzumab Govitecan, Pembrolizumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 15
States / cities: Stamford, Connecticut • Miami, Florida • Plantation, Florida + 12 more

Conditions: Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 64
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 54 more

Conditions: Metastatic Triple-negative Breast Cancer
Interventions: Relatlimab FDC + Nivolumab, Sacituzumab Govitecan (SG), Nivolumab; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Solid Tumor
Interventions: IDE397, Sacituzumab govitecan; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 15
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Duarte, California + 11 more

Conditions: Squamous Cell Carcinoma of Head and Neck, Sinus Cancer, Nasal Cavity Cancer, Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer, Oral Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions: Sacituzumab Govitecan, Cetuximab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Cervical Cancer
Interventions: Sacituzumab Tirumotecan, Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 686 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 38
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 35 more

Conditions: Triple Negative Breast Cancer
Interventions: Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 1,514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 188
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 158 more

Conditions: Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
Interventions: Pembrolizumab, Sacituzumab Govitecan; Drug
Lead sponsor: Ana C Garrido-Castro, MD; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 8
States / cities: Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 5 more

Conditions: Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Interventions: Sacituzumab tirumotecan, Enfortumab Vedotin, Pembrolizumab, Supportive care measures; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 8
States / cities: San Francisco, California • Chicago, Illinois • Indianapolis, Indiana + 5 more

Conditions: Gastrointestinal Cancer
Interventions: Capecitabine, Sacituzumab govetican; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Metastatic Urothelial Carcinoma
Interventions: Ipilimumab, Nivolumab, Sacituzumab govitecan; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Sacituzumab tirumotecan, Pemetrexed, Carboplatin, H1 Receptor Antagonist, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 17
States / cities: Oakland, California • Roseville, California • San Francisco, California + 13 more

Conditions: Triple Negative Breast Cancer
Interventions: Trilaciclib, Sacituzumab Govitecan-hziy; Drug
Lead sponsor: G1 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 22
States / cities: Chandler, Arizona • Bakersfield, California • Los Angeles, California + 18 more

Conditions: Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, HER2-negative Breast Cancer
Interventions: Sacituzumab Govitecan, Pembrolizumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 5
States / cities: Boston, Massachusetts • Danvers, Massachusetts • Newton, Massachusetts

Search by objective public record fields.

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Saci Nivo Rela for TNBC

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Sacituzumab Govitecan In TNBC